
    
      Outpatient smokers who are depressed despite current stable psychiatric medication regimens
      will be invited to participate.

      They will receive varenicline dosed according to FDA-approved smoking cessation regime;
      patients will be assessed using QIDS-SR16, snaith-hamilton anhedonia rating scale, SAFTEE and
      clinical global improvement self-report scales and clinician global improvement scales at the
      above time intervals.

      Concurrent medication, psychiatric and non-psychiatric, will be recorded, as will vital signs
      (BP, HR, weight) and tobacco use.
    
  